The 2022 annual ESMO meeting featured a plethora of interesting presentations in the field of breast cancer (BC). In the hormone-sensitive setting, data were presented on the effect of extending adjuvant aromatase inhibitor therapy in patients with early-stage disease. In the metastatic setting, interesting updates were presented with CDK4/6 inhibitors, while other abstracts reported the potential of selective oestrogen receptor modulators or degraders. In addition, updated results were presented for the TROPiCS-02 study evaluating the antibody-drug conjugate sacituzumab govitecan in pre-treated patients with HR+/HER2− metastatic breast cancer. Finally, metronomic treatment with vinorelbine plus cyclophosphamide and capecitabine proved to be another feasible treatment strategy in this setting. In triple-negative breast cancer (TNBC), (neo)adjuvant data with pembrolizumab were presented together with emerging results on the use of the anti-CD73 agent oleclumab in patients with advanced TNBC. We are very grateful to Prof. Hans Wildiers and Dr. Kevin Punie for their help in making the abstract selection for this article.
(Belg J Med Oncol 2022;16(8):387–94)
